The healthcare burden is increasing in both the developed and the developing world and there is widespread acceptance that the historical pharmaceutical business model is not sustainable. In order to meet the healthcare challenge, companies and academia need to develop new business models to increase the probability of success and decrease the cost of failure. New partnerships have already emerged in the area of neglected diseases and other models for diseases of the developed world are emerging.
No takes yet. Share an insight, caveat, or question.
Jackie Hunter (2011) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: